ROCKY MOUNTAIN CANCER CENTERS
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- -
PSMA PET Imaging Transforms Prostate Cancer Management with Multiple FDA-Approved Agents
PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.
Survey Reveals Challenges in Venetoclax Adoption for CLL Treatment in Community Settings
A recent survey of 103 oncologist-hematologists shows tumor lysis syndrome management and clinical logistics are primary concerns in venetoclax initiation for CLL treatment.
Mosunetuzumab Shows Promise in Follicular Lymphoma, Ongoing Trials Explore Efficacy
Mosunetuzumab demonstrates a high objective response rate of 95% and a complete metabolic response rate of 83.3% in previously untreated, low-tumor burden follicular lymphoma patients.
Expert Outlines Strategies to Improve Access and Diversity in HR+/HER2- Breast Cancer Clinical Trials
Dr. Mabel Mardones emphasizes the critical importance of bringing clinical trials to community settings, highlighting the need for collaboration between pharmaceutical companies, academic centers, and community practices.
Oncology Leaders Emphasize Cautious AI Implementation to Maintain Physician Trust
Rocky Mountain Cancer Centers' executive director warns that inaccurate AI outputs could damage physician confidence in the technology for months, emphasizing the need for careful implementation.